Literature DB >> 15806480

Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?

Ziyad Al Aly1, Jennifer M Philoctête Ashley, Mary E Gellens, Esther A González.   

Abstract

Thrombotic thrombocytopenic purpura (TTP), characterized by thrombocytopenia and microangiopathic hemolytic anemia, is a relatively rare disorder. The majority of cases have no defined causes. TTP has been reported in association with many drugs, but not with imatinib mesylate. We report a 22-year-old African-American woman who developed idiopathic hypereosinophilic syndrome. She was treated with imatinib mesylate and subsequently developed microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. TTP was diagnosed. A kidney biopsy was performed and was diagnostic of thrombotic microangiopathy. The patient was treated with plasma exchange and hemodialysis. Her eosinophilia resolved, but she remained dialysis dependent. To our knowledge, this is the first case report of the possible association between imatinib mesylate and TTP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15806480     DOI: 10.1053/j.ajkd.2004.12.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

Review 1.  Thrombotic microangiopathy with targeted cancer agents.

Authors:  John A Blake-Haskins; Robert J Lechleider; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

Review 2.  Chemotherapy-associated renal dysfunction.

Authors:  Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal:  Nat Rev Nephrol       Date:  2009-06-30       Impact factor: 28.314

Review 3.  Hematologic toxicities of small molecule tyrosine kinase inhibitors.

Authors:  Nicholas A Barber; Wais Afzal; Mojtaba Akhtari
Journal:  Target Oncol       Date:  2011-11-30       Impact factor: 4.493

4.  A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib.

Authors:  Suella Martino; Etienne Daguindau; Christophe Ferrand; Jamal Bamoulid; Sandrine Hayette; F-E Nicolini; G Capellier; Eric Deconinck; Fabrice Larosa
Journal:  Leuk Res Rep       Date:  2013-03-19

5.  Renal involvement in idiopathic hypereosinophic syndrome.

Authors:  Nathalie Shehwaro; Anne Lyse Langlois; Victor Gueutin; Hassane Izzedine
Journal:  Clin Kidney J       Date:  2013-06

6.  Minimal change disease onset observed after bevacizumab administration.

Authors:  Ramy M Hanna; Eduardo Lopez; James Wilson; Shrinath Barathan; Arthur H Cohen
Journal:  Clin Kidney J       Date:  2015-12-28

Review 7.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

Review 8.  Cancer-associated thrombotic microangiopathy.

Authors:  K Govind Babu; Gita R Bhat
Journal:  Ecancermedicalscience       Date:  2016-06-28

9.  Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.

Authors:  Maureen Assayag; Philippe Rouvier; Marion Gauthier; Ghania Costel; Philippe Cluzel; Lucile Mercadal; Gilbert Deray; Corinne Isnard Bagnis
Journal:  BMC Cancer       Date:  2017-11-16       Impact factor: 4.430

Review 10.  Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.

Authors:  Terry King-Wing Ma; Stephen P McAdoo; Frederick Wai Keung Tam
Journal:  Nephrol Dial Transplant       Date:  2017-01-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.